Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells
| Autor: | André B.P. van Kuilenburg, Jerry Hoebink, René Leen, Annemieke J.M. de Ruijter, Huib N. Caron |
|---|---|
| Přispěvatelé: | Amsterdam Gastroenterology Endocrinology Metabolism, Cancer Center Amsterdam, Laboratory Genetic Metabolic Diseases, Other departments, Amsterdam Public Health, Paediatric Oncology |
| Jazyk: | angličtina |
| Rok vydání: | 2006 |
| Předmět: |
Antimetabolites
Antineoplastic Cancer Research Cell cycle checkpoint medicine.drug_class Biology Hydroxamic Acids Deoxycytidine Neuroblastoma chemistry.chemical_compound Tumor Cells Cultured medicine Humans Enzyme Inhibitors Cell Cycle Histone deacetylase inhibitor Cell Differentiation medicine.disease Gemcitabine Molecular biology Histone Deacetylase Inhibitors Drug Combinations Oncology chemistry Cell culture Apoptosis Cancer cell Cancer research medicine.drug |
| Zdroj: | Cancer letters, 233(2), 240-246. Elsevier Ireland Ltd |
| ISSN: | 0304-3835 |
| Popis: | Additive to synergistic induction of apoptosis has been reported as a result of sequential incubation of cancer cells with a histone deacetylase inhibitor (HDACi) and gemcitabine (dFdC), a deoxycytidine analogue with proven anti-tumour activity. This study shows that sequential treatment of two neuroblastoma cell lines with BL1521, an HDACi, and dFdC resulted in strong antagonism despite a minor increase of dFdCTP incorporation into the DNA of one cell line. Furthermore, no difference in the deoxycytidine kinase activity was observed in response to BL1521. In conclusion, cancer cells that respond to HDACi with a cell cycle arrest and differentiation may no longer be sensitive to dFdC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect